Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0007097 (carcinoma)
 152,788 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Estramustine phosphate disodium (Estracyt) was used in the treatment of 38 patients with prostatic carcinoma for at least 1 year. Of these patients 37 patients were treated with Estracyt as primary treatment and 1 patient had been treated with another antiandrogenic therapy before the Estracyt treatment. Estracyt was given orally in a dose of 560 mg/day in divided oral doses. The clinical evaluation was done for the change of PAP, the relapse rate, the survival rate and the side effect. Among 22 cases which had shown abnormally high PAP values before the treatment started, the values decreased or normalized in 21 cases (95.5%) in the first year of administration of Estracyt. In 6 cases, however, the values increased again in the second year or later. Relapse was observed in 10 (26.3%) out of 38 cases. Relapse rate was 2.6%, 51.7%, and 51.7%, at the first, third, and fifth year, respectively. Survival rate was 97.4% at the first year, 88.5% at the third year, and 68.8% at the fifth year for the follow-up study. Side effects were observed in 14 (36.8%) out of 38 cases. The main side effect was gynecomastia. Gastro-intestinal disturbance and edema were also observed. However, there were only 2 cases (5.2%) in which administration of Estracyt had to be discontinued.
 ...
PMID:[Clinical study of estramustine phosphate disodium (Estracyt) on prostatic cancer--results of long-term therapy for 38 patients with prostatic cancer]. 228 16

Cervical carcinoma cell lines produce several polypeptide hormones. While screening human cervical cancers for such factors we have found many tumors to be immunoreactive for opioid peptides. The tumors were collected at surgery or prior to actinotherapy, fixed in buffered formalin, paraffin-embedded, and immunocytochemically stained using the PAP method. The localization of opioid-like immunoreactivity was investigated using a primary antiserum recognizing the Tyr-Gly-Gly-Phe sequence common to all known opioid peptides. The presence of neuropeptide Y (NPY) and peptide histidine methionine (PHM), both known to be present in normal human cervical tissue, was also investigated using specific antisera. Controls included staining controls and absorption controls, using Sepharose-coupled antigen and were all negative. Out of 40 cervical carcinomas, 27 displayed varying numbers of opioid-immunoreactive cells. In 12 normal cervical specimens no specific staining was observed. None of the tumors displayed any NPY-like or PHM-like immunoreactivity. The growth of cervical carcinoma seems therefore to be accompanied by a destruction of the local peptidergic innervation of blood vessels and smooth muscle cells. The demonstration of opioid-like immunoreactants and the known immunoregulatory properties of these peptides, indicate that opioid peptides may be important in the regulation of growth of human cervical carcinoma.
 ...
PMID:Opioid-like immunoreactants in human cervical cancer. 229 15

Nine cases of inflammatory invasive carcinoma of the uterine cervix are reviewed. All appeared in women under less than fifty years old, quickly after normal PAP smears. They occupied the endocervix, which mean diameter was 5 cm and outcome was very poor with only one survivor: four patients were free of disease in the pelvis and relapsed outside, the others underwent a local regional failure in less than 2 years. Association of radiotherapy and surgery is mandatory for stage IB and IIA FIGO; radiotherapy modalities--brachytherapy, external irradiation followed by brachytherapy--must be chosen according to tumor volume, size of the cervix, anatomy of vagina. For other stages radiotherapy alone is recommended using hyperfractionated treatment; in the future such observation would be documented by cytofluorometry analysis and/or molecular biology approach.
 ...
PMID:[Inflammatory carcinoma of the uterine cervix. Review of 9 cases]. 232 41

Thirty-one cases of thyroid malignancies which were originally classified as anaplastic carcinoma were reexamined immunohistochemically using PAP methods (peroxidase:antiperoxidase) for IgM, IgG, IgA, cytokeratin, calcitonin, lysozyme and alpha-1-antitrypsin. The reclassification results were compared with patient data such as clinical symptoms, treatment modalities, and clinical outcome. Postoperative radiotherapy was carried out in more than 80% of cases, chemotherapy in none. Seven of 31 tumors showed a positive staining for IgM (n = 4), IgG (n = 2), and IgA (n = 1) antibodies. All of these cases were negative for epithelial markers. Surprisingly, not only all small cell tumors (n = 3) but also 4 tissues with predominantly giant cell areas were among those reclassified as primary malignant lymphoma.
 ...
PMID:Immunohistochemical reclassification of anaplastic carcinoma reveals small and giant cell lymphoma. 236 31

The clinical usefulness of PAP and PA as a tumor marker for the prostate cancer were discussed. The materials for this study were 1385 cases which contained 158 cases with prostatic carcinoma. The positive rate of serum PAP and PA were 77.7% and 94.1% in untreated prostatic carcinoma and 15.1% and 70.0% in benign prostatic hypertrophy using 3.0 ng/ml as an upper limit of normal controls of serum PAP and PA. The cut off level in serum PA should be discussed more. PA was not superior to PAP as a tumor marker in the series, but our results have suggested the simultaneous assay of serum PAP and PA is valuable in detection and following-up of prostate cancer.
 ...
PMID:[Tumor markers of prostate cancer--evaluation of serum PAP and PA]. 241 65

The biological diagnosis of prostatic carcinoma in relation with benign prostatic hypertrophy is essentially realized by the evaluation of plasma PAP or medullar PAP, the increase of which rises to 70% of the cases. This evaluation contains also other biochemical markers such as CK-BB, glucose-6-phosphate dehydrogenase, LDH 5 or alkaline phosphatase. The elevation of urinary polyamines is also correlated with the evolution of carcinoma. Other markers have been recently described such as PSA, useful both by evaluation in serum and by its identification on biopsy in histopathology. This exploration could be completed by the evaluation of androgenic receptors and of circulating androgens.
 ...
PMID:[Cancer of the prostate: the markers other than prostatic acid phosphatase]. 241

A PAP immunoperoxidase method for demonstration of endogenous prolactin was applied to gastrectomy specimens from 10 patients with gastric ulcers and 154 patients with gastric carcinomas. For gastric ulcers and intact areas of carcinomabearing specimens, the results indicated a positive correlation by demonstration of prolactin in sites of active cellular proliferation such as regenerative epithelium over ulcer beds, neck cells of gastric mucosa proper and the lower third of intestinalized gastric mucosa. In contrast, prolactin was demonstrated in 84 of 154 gastric carcinoma patients with no apparent correlation to the clinical features. However, correlation became manifest after exclusion of 52 patients with poorly differentiated adenocarcinoma (por) because of their unevenly heavy distribution in advanced clinical stages. For the remaining 96 patients with carcinomas other than por, the rate of positive prolactin increased according to the depth of invasion from 10/29 in m & sm to 3/4 in si & sei, the scope of lymph node metastasis from 20/40 in n0 to 4/4 in n3 & n4 and the clinical stages from 12/26 in stage 1 to 15/22 in stage 4. These results suggest a growth promoting role of prolactin on benign and malignant gastric mucosa.
 ...
PMID:[Prolactin in gastric carcinomas: immunohistochemical demonstration with clinicopathologic correlation]. 242 63

The clinical features of a new prostate tumor marker, prostate-specific antigen (prostate antigen, PA), has been reviewed. Although PA cannot be used in early detection of prostate cancer, simultaneous determination of PA and PAP yields an additive clinical value in immuno-diagnosis of prostate cancer. At the present stage of development, PA is most useful as a prognostic marker for monitoring disease recurrence and treatment response. Also, PA is an effective immunohistologic marker for differential diagnosis of metastatic carcinomas with unknown primary, especially in the identification of metastatic prostate tumor in distant metastases and in the differentiation of primary prostate carcinoma from poorly differentiated transitional cell carcinoma of the bladder. Unequivocal evidence is not yet available on the role of circulating PA-binding globulin as an auto-antibody or an anti-tumor antibody as a result of patient's immune response. This observation is of clinical value for investigation of prostate cancer biology. The intriguing protease activity as detected in PA may provide new avenues for prostate cancer research.
 ...
PMID:What's new in tumor markers for prostate cancer? 242 64

We evaluated the analytical performance of a new monoclonal immunoradiometric assay ("M-PSA") for prostate-specific antigen ("Tandem"; Hybritech Inc.) in comparison with a monoclonal immunoradiometric assay ("M-PAP") for mass measurement of prostatic acid phosphatase ("Tandem") and with a conventional enzyme-activity assay ("E-PAP") for prostatic acid phosphatase (EC 3.1.3.2). For M-PSA, the CVs were 1.3-3.0% within-run and 3.0-4.9% between-run. The minimum detectable mass concentration was 0.10 microgram/L, and linearity extended to 100 micrograms/L. The reference interval for M-PSA in 178 healthy men was 0-2.8 micrograms/L. Serum specimens from men with prostatic disease (primarily prostatic carcinoma and benign prostatic hypertrophy) were assayed by the three methods. Correlation was best between mass measurement (M-PAP) and enzyme activity (E-PAP) for prostatic acid phosphatase (r = 0.958). Results for PSA did not correlate well with those for either M-PAP (r = 0.629) or E-PAP (r = 0.387). PSA was increased in a higher percentage of specimens from men with earlier (clinical stage B) prostatic carcinoma than were results from either assay for PAP.
 ...
PMID:Evaluation of a monoclonal immunoradiometric assay for prostate-specific antigen. 244 7

Primary liver carcinoma (PLC) may express a certain number of markers. Here we communicate results of an analysis of five such markers (alpha-1-antitrypsin--AAT--, carcino-embryonic antigen --CEA--, alpha-fetoprotein --AFP--, and superficial --HBsAg-- and core --HBcAg-- antigens of hepatitis B virus) by means of PAP techniques in 130 cases of PLC, comparing the neoplastic tissue and the non-tumorous liver. Three variants of PLC are distinguished: hepatocarcinoma (HC) (108 cases); cholangiocarcinoma (CC) (19 cases); and three cases of hepatocholangiocarcinoma (HCC). AAT was positive in 29 HC, 2 HCC, and negative in all 19 CC. CEA appeared positive in 16 HC, 16 CC and only one HCC. AFP was positive in two HC, and negative in all CC and HCC. HBsAg displayed positivity in 15 HC and one HCC, being negative in all 19 CC. HBcAg was positive in 4 HC, and negative in all CC and HCC. HBsAg was also positive in two neoplastic emboli associated with HC. On the non-tumorous liver tissue the immunohistochemical results showed positivity for AAT and CEA, but not for AFP. Therefore the present results confirm that in the geographical area from which these tumors proceed, PLC is closely correlated with HBsAg positivity and with cirrhosis.
 ...
PMID:Immunohistochemical characterization of 130 cases of primary hepatic carcinomas. 244 80


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>